Adamis Pharmaceuticals Corporation [NASDAQ: ADMP] loss -4.59% on the last trading session, reaching $0.63 price per share at the time. Adamis Pharmaceuticals Corporation represents 66.50 million in outstanding shares, while the company has a total market value of $44.90 million with the latest information. ADMP stock price has been found in the range of $0.58 to $0.65.
If compared to the average trading volume of 1.54M shares, ADMP reached a trading volume of 2093984 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Here is what top equities market gurus are saying about Adamis Pharmaceuticals Corporation [ADMP]:
Maxim Group have made an estimate for Adamis Pharmaceuticals Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 13, 2020. The new note on the price target was released on February 27, 2020, representing the official price target for Adamis Pharmaceuticals Corporation stock. On July 16, 2019, analysts decreased their price target for ADMP shares from 1.90 to 1.10.
The Average True Range (ATR) for Adamis Pharmaceuticals Corporation is set at 0.06, with the Price to Sales ratio for ADMP stock in the period of the last 12 months amounting to 2.05. The Price to Book ratio for the last quarter was 1.26, with the Price to Cash per share for the same quarter was set at 0.15.
Trading performance analysis for ADMP stock
Adamis Pharmaceuticals Corporation [ADMP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.54. With this latest performance, ADMP shares gained by 25.03% in over the last four-week period, additionally plugging by 13.81% over the last 6 months – not to mention a drop of -56.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMP stock in for the last two-week period is set at 67.53, with the RSI for the last a single of trading hit 70.42, and the three-weeks RSI is set at 62.99 for Adamis Pharmaceuticals Corporation [ADMP]. The present Moving Average for the last 50 days of trading for this stock 0.4522, while it was recorded at 0.5686 for the last single week of trading, and 0.6253 for the last 200 days.
Adamis Pharmaceuticals Corporation [ADMP]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adamis Pharmaceuticals Corporation [ADMP] shares currently have an operating margin of -135.67 and a Gross Margin at +17.80. Adamis Pharmaceuticals Corporation’s Net Margin is presently recorded at -132.53.
Return on Total Capital for ADMP is now -67.13, given the latest momentum, and Return on Invested Capital for the company is -69.60. Return on Equity for this stock declined to -70.85, with Return on Assets sitting at -54.46. When it comes to the capital structure of this company, Adamis Pharmaceuticals Corporation [ADMP] has a Total Debt to Total Equity ratio set at 11.32. Additionally, ADMP Total Debt to Total Capital is recorded at 10.17, with Total Debt to Total Assets ending up at 8.28. Long-Term Debt to Equity for the company is recorded at 4.11, with the Long-Term Debt to Total Capital now at 3.69.
Reflecting on the efficiency of the workforce at the company, Adamis Pharmaceuticals Corporation [ADMP] managed to generate an average of -$171,385 per employee. Receivables Turnover for the company is 14.58 with a Total Asset Turnover recorded at a value of 0.41.Adamis Pharmaceuticals Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
Adamis Pharmaceuticals Corporation [ADMP]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adamis Pharmaceuticals Corporation posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMP.
An analysis of insider ownership at Adamis Pharmaceuticals Corporation [ADMP]
There are presently around $8 million, or 15.70% of ADMP stock, in the hands of institutional investors. The top three institutional holders of ADMP stocks are: CVI HOLDINGS, LLC with ownership of 3,397,916, which is approximately New of the company’s market cap and around 1.80% of the total institutional ownership; ANSON FUNDS MANAGEMENT LP, holding 3,013,054 shares of the stock with an approximate value of $1.99 million in ADMP stocks shares; and VANGUARD GROUP INC, currently with $1.25 million in ADMP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Adamis Pharmaceuticals Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 21 institutional holders increased their position in Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] by around 6,834,219 shares. Additionally, 7 investors decreased positions by around 60,837 shares, while 22 investors held positions by with 4,688,121 shares. The mentioned changes placed institutional holdings at 11,583,177 shares, according to the latest SEC report filing. ADMP stock had 13 new institutional investments in for a total of 6,788,525 shares, while 2 institutional investors sold positions of 17,989 shares during the same period.